| Emma Medina, MD | |
|
140 Lockwood Ave Ste 310, New Rochelle, NY 10801-4909 | |
| (914) 632-1600 | |
| (914) 576-4770 |
| Full Name | Emma Medina |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 140 Lockwood Ave Ste 310, New Rochelle, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710061973 | NPI | - | NPPES |
| 0367045 | Other | CIGNA | |
| 0046926 | Other | AETNA | |
| 0066930 | Other | NY | GHI |
| 00863727 | Medicaid | NY | |
| WS902 | Other | NY | OXFORD |
| 2C4799 | Other | NY | HEALTHNET |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 143497 (New York) | Primary |
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.
A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
About three-fourths of individuals with insomnia report experiencing the condition for at least one year and almost half experience it for three years, according to a report in the March 9 issue of Archives of Internal Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emma Medina, MD 140 Lockwood Ave Ste 310, New Rochelle, NY 10801-4909 Ph: (914) 632-1600 | Emma Medina, MD 140 Lockwood Ave Ste 310, New Rochelle, NY 10801-4909 Ph: (914) 632-1600 |
News Archive
Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.
A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
About three-fourths of individuals with insomnia report experiencing the condition for at least one year and almost half experience it for three years, according to a report in the March 9 issue of Archives of Internal Medicine.
› Verified 4 days ago
Dr. Daniel Harold Pomerantz, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 16 Guion Pl, New Rochelle, NY 10801 Phone: 914-365-3615 Fax: 914-365-5453 | |
Richard Gottfried, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1296 North Ave, New Rochelle, NY 10804 Phone: 914-235-8224 Fax: 914-235-6940 | |
Dr. Michele Halpern, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 16 Guion Pl, New Rochelle, NY 10801 Phone: 914-632-5000 | |
Dr. Gerald Edmund Thomson, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 85 Premium Point, New Rochelle, NY 10801 Phone: 914-633-5547 | |
Donald Scott Miller, MD Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 20 Cedar St Fl 2, New Rochelle, NY 10801 Phone: 914-633-7870 Fax: 914-633-7626 | |
Dr. Melvyn S Bleiberg, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 80 Oxford Rd, New Rochelle, NY 10804 Phone: 914-576-6783 | |
Dr. Frank M Tamarin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 175 Memorial Hwy, Suite 3-6, New Rochelle, NY 10801 Phone: 914-235-7302 Fax: 914-636-6030 |